Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$13.72 USD

13.72
4,949,991

+1.17 (9.32%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $13.72 0.00 (0.00%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

Zacks Equity Research

Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?

by Zacks Equity Research

Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?

Zacks Equity Research

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Zacks Equity Research

AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

by Zacks Equity Research

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Zacks Equity Research

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft

by Zacks Equity Research

AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.

Zacks Equity Research

AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

by Zacks Equity Research

Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Tirthankar Chakraborty headshot

4 Must-Buy Stocks for Remarkable Earnings Acceleration

by Tirthankar Chakraborty

Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).

Zacks Equity Research

AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Zacks.com featured highlights AxoGen, Western Digital and Gen Digital

by Zacks Equity Research

AxoGen, Western Digital and Gen Digital have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Best Stocks to Buy for Remarkable Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.

Zacks Equity Research

Here's Why Momentum in AxoGen (AXGN) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group

by Zacks Equity Research

AxoGen, Western Digital, Accolade and Credo Technology Group are part of the Screen of the Week article.

Tirthankar Chakraborty headshot

4 Top Stocks That Flaunt Solid Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.

Zacks Equity Research

Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group

by Zacks Equity Research

Aspen Aerogels, AxoGen and Credo Technology Group are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Stocks Worth a Look for Solid Earnings Acceleration

by Tirthankar Chakraborty

Keep a tab on stocks such as Aspen Aerogels (ASPN), AxoGen (AXGN) and Credo Technology Group (CRDO) for superb earnings acceleration.

Zacks Equity Research

Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Dynatronics Corporation (DYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.